Markets
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Kala Pharmaceuticals (KALA – Research Report), with a price target of $49.00. The company’s shares closed last Wednesday at $7.63.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 9.8% and a 43.7% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Eiger Biopharmaceuticals, and Lexicon Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kala Pharmaceuticals with a $26.00 average price target, representing a 270.4% upside. In a report issued on April 9, J.P. Morgan also maintained a Buy rating on the stock with a $17.00 price target.